Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous ΔF508 mutation

被引:36
|
作者
Sermet-Gaudelus, I
Vallée, B
Urbin, I
Torossi, T
Marianovski, R
Fajac, A
Feuillet, MN
Bresson, JL
Lenoir, G
Bernaudin, JFO
Edelman, A
机构
[1] Fac Necker, INSERM, U467, F-75015 Paris, France
[2] Hop Necker Enfants Malad, Dept Pediat, F-75015 Paris, France
[3] Hop Necker Enfants Malad, Dept Otorhinolaryngol, F-75015 Paris, France
[4] Univ Paris 06, Lab Histol & Biol Tumorale, Hop Tenon, F-75020 Paris, France
[5] Hop Necker Enfants Malad, Serv Genet, F-75015 Paris, France
[6] Hop Necker Enfants Malad, Ctr Invest Clin, F-75015 Paris, France
关键词
D O I
10.1203/01.PDR.0000032981.64413.AD
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Cystic fibrosis (CF) is caused by mutations of the gene encoding for the CFTR (CF transmembrane conductance regulator) protein. The most frequent mutation, the DeltaF508 mutation, results in a defective cAMP-regulated chloride transport in the epithelial cells. The spectrum of clinical manifestations in patients bearing homozygous DeltaF508 mutations can vary considerably, suggesting that, in the patients with a mild disease, CFFR could be partly functional. To test this hypothesis, we explored in nasal ciliated epithelial cells (NCC) of 9 control subjects and 23 DeltaF508 homozygous patients the anion conductive pathway by a halide sensitive fluorescent dye assay SPQ (6-methoxy-N-3'-sulfopropylquinolinium) and the CFTR transcript levels by RT-PCR. As 50% represented the lowest fraction of the control subjects NCC demonstrating a cAMP-dependent conductance, a CF patient was considered as "cAMP responder" if at least 50% of the NCC tested displayed a cAMP-dependent conductive pathway. According to these criteria, 8 of the 23 patients were considered as cAMP responders. They had a significantly less severe disease considering the respiratory function and infectious status. The amount of CFTR mRNA did not differ between the control subjects and the patients. No statistical correlation could be found between the transcript level and the expression of a cAMP conductive pathway. This cAMP-dependent Cl- conductance detected in homozygous NCC could be due to a residual CFFR activity and may explain the mild phenotypes observed in some DeltaF508 homozygous patients.
引用
收藏
页码:628 / 635
页数:8
相关论文
共 50 条
  • [41] Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the ΔF508 mutation.: F508 deletion disrupts a kinase-binding site (Retraction of vol 282, pg 10804, 2007)
    Treharne, Kate J.
    Crawford, Russell M.
    Xu, Zhe
    Chen, Jeng-Haur
    Best, O. Giles
    Schulte, Eva A.
    Gruenert, Dieter C.
    Wilson, Stuart M.
    Sheppard, David N.
    Kunzelmann, Kar
    Mehta, Anil
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (36) : 25103 - 25103
  • [42] Structure-Activity Relationships of Cyanoquinolines with Corrector-Potentiator Activity in ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator Protein
    Knapp, John M.
    Wood, Alex B.
    Puay-Wah Phuan
    Lodewyk, Michael W.
    Tantillo, Dean J.
    Verkman, A. S.
    Kurth, Mark J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 1242 - 1251
  • [43] Impact of the ΔF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure
    Lewis, HA
    Zhao, X
    Wang, C
    Sauder, JM
    Rooney, I
    Noland, BW
    Lorimer, D
    Kearins, MC
    Conners, K
    Condon, B
    Maloney, PC
    Guggino, WB
    Hunt, JF
    Emtage, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (02) : 1346 - 1353
  • [44] Modulation of ΔF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids
    Lim, M
    McKenzie, K
    Floyd, AD
    Kwon, E
    Zeitlin, PL
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2004, 31 (03) : 351 - 357
  • [45] Cystic fibrosis in ukraine: Age, origin and tracing of the Delta F508 mutation
    Livshits, LA
    Kravchenko, SA
    GENE GEOGRAPHY, 1996, 10 (03): : 219 - 227
  • [46] Cystic fibrosis Δf508 mutation screening in Brazilian women with altered fertility
    Brunoro, G. V. F.
    Wolfgramm, E. V.
    Louro, I. D.
    Degasperi, I. I.
    Busatto, V. C. W.
    Perrone, A. M. S.
    Batitucci, M. C. P.
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (07) : 4343 - 4346
  • [47] Cystic fibrosis Δf508 mutation screening in Brazilian women with altered fertility
    G. V. F. Brunoro
    E. V. Wolfgramm
    I. D. Louro
    I. I. Degasperi
    V. C. W. Busatto
    A. M. S. Perrone
    M. C. P. Batitucci
    Molecular Biology Reports, 2011, 38 : 4343 - 4346
  • [48] Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator
    Luciani, Alessandro
    Villella, Valeria Rachela
    Esposito, Speranza
    Gavina, Manuela
    Russo, Ilaria
    Silano, Marco
    Guido, Stefano
    Pettoello-Mantovani, Massimo
    Carnuccio, Rosa
    Scholte, Bob
    De Matteis, Antonella
    Maiuri, Maria Chiara
    Raia, Valeria
    Luini, Alberto
    Kroemer, Guido
    Maiuri, Luigi
    AUTOPHAGY, 2012, 8 (11) : 1657 - 1672
  • [49] Epithelial IgG and its relationship to the loss of F508 in the common mutant form of the cystic fibrosis transmembrane conductance regulator
    Treharne, Kate J.
    Cassidy, Diane
    Goddard, Catharine
    Colledge, William H.
    Cassidy, Andrew
    Mehta, Anil
    FEBS LETTERS, 2009, 583 (15): : 2493 - 2499
  • [50] Potent s-cis-locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy
    Yu, Gui Jun
    Yoo, Choong L.
    Yang, Baoxue
    Lodewyk, Michael W.
    Meng, Liping
    El-Idreesy, Tamer T.
    Fettinger, James C.
    Tantillo, Dean J.
    Verkman, A. S.
    Kurth, Mark J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (19) : 6044 - 6054